HB 625 shifts responsibility for collecting fees from research facilities to the Maryland Department of Agriculture, replacing the current system under the Department of Health. It requires facilities submitting USDA Form 7023 (for animal testing) to pay annual contributions based on animal count: $5,000 for ≤100 animals, $10,000 for 101-500, $55,000 for 501-5,000, and $75,000 for over 5,000. Funds collected will support the Human-Relevant Research Fund established under Maryland’s Economic Development Article. The bill repeals existing health code provisions and creates new agriculture code sections for this fee structure, effective October 2026.
HB 1109 creates the Maryland Medical Reserve Corps, a statewide volunteer network for emergencies like disease outbreaks or disasters, managed by the Maryland Department of Health. It requires the Department to notify county health officers about procurement opportunities for electronic health records systems, allowing counties to join without state approval if fully funded locally. The bill establishes a Public Health Workforce Development Fund (using interest earnings and transfers from another fund) and mandates the Department of Legislative Services to assess health equity impacts of new legislation. These changes directly affect county health departments, the Department of Health, and public health workforce planning.
HB 1367 establishes a Commission on Re-Imagining Health Care in Maryland to study and recommend changes for a new statewide healthcare system. The commission, composed of 20 appointed members including state officials, healthcare providers, insurers, county representatives, and community members, will examine how healthcare is delivered in other regions and address issues like provider shortages, cost balancing, and system integration. It will specifically study how to create a patient-centered system covering all health needs, eliminate access barriers, and ensure financial sustainability for all Maryland residents. The commission’s final recommendations, due by 2028, would guide potential future policy changes but do not enact any immediate healthcare reforms.
SB 772 requires the Maryland Department of Health to create and maintain a public database of employment training and job placement programs. The database will help residents find opportunities that can lead to eligibility for Medicaid (Maryland Medical Assistance Program) and SNAP (Supplemental Nutrition Assistance Program), including program details, application steps, and direct contact options. The Department must update the database every 30 days and assist individuals in enrolling in listed programs. Other state agencies, including the Department of Labor and Department of Human Services, must recommend programs for inclusion. This bill directly affects Maryland residents seeking to improve employment prospects while maintaining access to critical health and nutrition benefits.
HB 1016 invalidates noncompete and conflict-of-interest clauses in employment contracts for certain employees if their employer relocates the majority of its employees or principal business location outside Maryland. It directly affects low-wage workers (earning ≤150% of state minimum wage), healthcare workers providing direct patient care (earning ≤$350,000 annually), and veterinary professionals. For high-earning healthcare workers ($350,000+), the bill allows limited 1-year noncompete restrictions within 10 miles of their prior workplace. The law takes effect October 1, 2026, and applies only to contracts signed after that date.
HB 1533 (the Crown and Care Act) bans 12 specific harmful ingredients - including certain phthalates, formaldehyde, mercury, and PFAS chemicals - from cosmetic products sold in Maryland. It directly affects cosmetic manufacturers, retailers, and salons by prohibiting the sale or distribution of products containing these ingredients, with limited exceptions for unavoidable trace amounts from manufacturing processes. The bill authorizes the Maryland Department of Health to investigate complaints, inspect businesses, and enforce penalties, while allowing consumers harmed by violations to seek civil damages and attorney fees. This law aims to protect public health by reducing exposure to chemicals linked to health risks like skin irritation and potential long-term harm.
SB 656 bans 12 specific harmful chemicals in cosmetics sold in Maryland, including formaldehyde, mercury, and certain PFAS chemicals. It creates civil liability for manufacturers or sellers who violate this ban, allowing consumers to sue for damages. The Maryland Department of Health gains authority to investigate complaints, inspect businesses, and collect product samples. The law exempts trace amounts of banned ingredients that occur unavoidably during manufacturing. The bill takes effect July 1, 2026.
HB 1135 allows pharmacists in Maryland to order certain vaccinations for patients aged 3 and older without needing to administer the vaccine themselves. Pharmacists must complete 20+ hours of approved training covering vaccine safety, injection techniques, and emergency response, hold current CPR certification, and report all vaccinations to the ImmuNet program. The bill specifically covers influenza, COVID-19, and emergency-use vaccines, and requires pharmacists to refer minors to pediatric care when ordering vaccines. This expands pharmacists' role in vaccine access while maintaining safety protocols and reporting requirements.
SB 773 allows pharmacists in Maryland to order certain vaccinations (like flu, COVID-19, or emergency vaccines) for patients aged 3 and older without needing to administer the vaccine themselves. To qualify, pharmacists must complete 20 hours of approved training, hold current CPR certification, and complete 2 hours of continuing education on immunizations. The bill requires pharmacists to follow written vaccine-specific protocols, report all vaccinations to Maryland’s ImmuNet registry, and refer pediatric patients to primary care providers when appropriate. This policy directly affects pharmacists, patients seeking these vaccines, and healthcare coordination for immunizations. The changes take effect October 1, 2026.
SB 778 creates a new "clinical research pharmacy permit" required for pharmacies conducting clinical trials in Maryland. It allows healthcare providers to own such pharmacies under specific conditions, including requiring a licensed pharmacist to be on-site at all times and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations from being classified as "practice of medicine," removing a licensing barrier for these activities. This directly affects pharmacies seeking to operate clinical trials, healthcare providers considering ownership, and the State Board of Pharmacy (as the permit issuer).
